Archives: Agenda

• Are we playing technology catch-up: What can we learn and adapt from other industries, and how can we implement this on scale despite increased regulation?
• Lots of clinical management systems are generic but do we have ones that are clinically focused: Are you reaching the right audience in the right way and how can CROs get recognized by biotechs?
• Recognizing the impact of technology solutions on the patients journey and ways to progress this even further
• How do smaller biotechs prepare their supply chains for IRT adoption and compliance?

Chair: Joshua Cox, Vice President of Clinical Data & Analytics Capabilities, Eli Lilly and Company

• Discuss why financial accruals for clinical and R&D activities are still so challenging after all these years
• Using real-life case studies, discuss common pain-points experienced by biopharma companies when it comes to financial accruals
• Ponder easy implementations you can consider for your accruals processes that can significantly improve efficiency and decrease pain

• Breaking through the complexity of phase 1 studies
• Prioritizing Phase 1 schedule
• Optimizing efficiencies for NDA-Enabling studies

• Understand the reliance of both patients and doctors alike on online resources for trial and disease awareness.
• Learn about a new technology solution to search for digital opinion leaders sharing content online about the therapeutic area
• Discover how to identify and track Digital Opinion Leaders across all social and online platforms
• Plan how to engage Digital Opinion Leaders in trial awareness

• Key considerations for medical device clinical development program at different stages
• Optimize protocol design using data-driven approaches
• Leveraging policy advantages of Asia-Pacific to accelerate the program timeline
• Important factors when selecting a contract research organization (CRO) or other partners to manage a successful medical device study

• Biopharma has historically focused on achieving regulatory approval for value creation
• Asset valuations at the time of licensing or sale can be increased by expanding research plans to address non-regulatory stakeholders
• At the same time, new innovations in R&D productivity can lower the cost of trials while better managing risks of trial success

This session will explore how the ICF can become a patient engagement tool.

• How do potential participants view consent forms?
• Changes to make the consent form to be more engaging.
• Practical tips for changing your consent template.
• Challenges that exist for implementing a different type of consent form.

• Future-proofing supply chains to endure greater long-term sustainability responsibilities
• Adhering to sustainable practices without adding cost and risk to already tight budgets
• Operational implications of striving for more sustainable trial design
• Collaborating with supplier ecosystems to drive sustainability goals
• Sharing best practice for circular supply chain strategies and creating win-win business opportunities

Chair: Joshua Cox, Vice President of Clinical Data & Analytics Capabilities, Eli Lilly and Company